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It is a well-established scientific observation that mammalian cells contain fidelity proteins that appear to protect
against and adapt to various forms of endogenous and exogenous cellular conditions. Loss of function or genetic
mutation of these fidelity proteins has also been shown to create a cellular environment that is permissive for the
development of tumors, suggesting that these proteins also function as tumor suppressors (TSs). While the first
identified TSs were confined to either the nucleus and/or the cytoplasm, it seemed logical to hypothesize that the
mitochondria may also contain fidelity proteins that serve as TSs. In this regard, it now appears clear that at least
two mitochondrial sirtuins function as sensing, watchdog, or TS proteins in vitro, in vivo, and in human tumor samples.
In addition, these new results demonstrate that the mitochondrial anti-aging or fidelity/sensing proteins, SIRT3 and
SIRT4, respond to changes in cellular nutrient status to alter the enzymatic activity of specific downstream targets to
maintain energy production that matches energy availability and ATP consumption. As such, it is proposed that loss of
function or genetic deletion of these mitochondrial genes results in a mismatch of mitochondrial energy metabolism,
culminating in a cell phenotype permissive for transformation and tumorigenesis. In addition, these findings
clearly suggest that loss of proper mitochondrial metabolism, via loss of SIRT3 and SIRT4, is sufficient to promote
carcinogenesis.
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Mammalian cells express proteins that protect against
endogenous and exogenous forms of cellular damage to
both monitor and maintain the integrity of a cell [1-3].
An extension of this observation would be that the loss
of function or genetic mutation of these genes creates a
cellular environment that is permissive for the develop-
ment and/or accumulation of cellular damage that can put
the cell at a significantly increased risk for several human
illnesses, including cancer [4-7]. Since it is unlikely that
evolutionary pressure selected for proteins in mammalian
cells to prevent carcinogenesis, these proteins are more* Correspondence: david.gius@northwestern.edu
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tect specific organelles from damage by agents that induce
genotoxic stress [8]. These proteins are often referred
to as tumor suppressors (TSs) as mice lacking these genes
tend to develop tumors, and in many cases, these TS
genes are deleted or mutated in human tumors [9,10].
While the first identified TSs were confined to either
the nucleus and/or the cytoplasm, it seems logical to
hypothesize that the mitochondria would also contain
fidelity proteins that would serve as TSs.
It now seems clear that the cellular processes that govern
or oversee aging, perhaps better defined as longevity, are di-
rected by a combination of complex genetic, biochemical,
and cellular pathways that appear to be regulated, at least
in part, by a relatively new gene family referred to as
sirtuins [11,12]. The sirtuin family genes are the human
and murine homologs of the Saccharomyces cerevisiae
Sir2 that have been shown to directly regulate both repli-
cative and overall lifespan [13,14] as well as longevity in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Overview of sirtuin biology. (A) Cellular localization of
the nuclear, cytoplasmic, and mitochondrial sirtuins. (B) Schematic
of the enzymatic function of mitochondrial sirtuins using SIRT3.
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these more primitive species, it appears that these genes
direct longevity, at least in some significant part, by silen-
cing telomeres and sub-telomeric regions, silent mating
type loci, and, crucially, the rDNA, suppressing formation
of rDNA circles [12,15].
In contrast, mammalian sirtuin members are associated
with numerous physiological roles including stress re-
sponse, regulation of metabolism, gene silencing, and
aging [16,17]. While it has not been shown that these
genes determine longevity in mammals, they do appear to
regulate critical signaling networks, and following stress,
several mice lacking one of the sirtuin genes develop
illnesses that mimic those observed in older humans
[12,18]. Sirtuins were initially discovered to function as
deacetyltransferases; however, it now appears that several
of the proteins also function as ribosyltransferases [19-21]
under specific conditions. Based on these results, it has
been proposed that the mammalian sirtuins play a signifi-
cant role, at least in part, in directing the acetylome signal-
ing network that has recently been shown to be critical in
regulating multiple cellular processes [22]. While this
represents only a part of the overall role of sirtuins in
mammalian biology, it now appears clear that this protein
family, in some significant way, directs the activity of
downstream targets via post-translational modifications
involving protein acetylation (Figure 1A) to maintain
cellular metabolic homeostasis [23].
Mammalian sirtuins are classified as class III histone
deacetylases, which are different than traditional class I
and II histone deacetylases (HDACs) [24,25]. Unlike
conventional HDACs, sirtuins have a variety of non-
histone substrates ranging from metabolic enzymes to
structural proteins as well as histones [15,19]. The func-
tion of sirtuins is very well conserved via a common
275-amino acid catalytic domain, and these proteins are
localized to the nucleus (SIRT1, 6, and 7), mitochondria
(SIRT3, 4, and 5), and cytoplasm (SIRT2) (Figure 1B)
[13]. Sirtuins are NAD+-dependent deacetylases, and
early on in the investigation of sirtuin biology, it was
assumed that their requirement for NAD+ implied that
their mechanistic activity was connected to cellular me-
tabolism, providing a link between sirtuin activity, energy,
and stress responses [26,27]. For instance, the mitochon-
drial sirtuins, SIRT3 and SIRT4, appear to respond to
changes in cellular and nutrient stress, resulting in the
activation of their deacetylase or ribosyltransferase ac-
tivity and hence in post-translational modifications of
downstream target proteins [27-31]. It is now well
established that SIRT3 deacetylation activity is activated
by caloric restriction (CR) and fasting [29-31], and this
induction of deacetylation activity also appears to protect
against the development of age-related human pathology,
including tumorigenesis [29,32]. While these results donot, a priori, directly connect sirtuins to longevity, they do
strongly suggest that sirtuins, including mitochondrial
sirtuins, play a role, at least in some significant part, in
the complex process of aging.Inflection points, aging, and human carcinogenesis
One fundamental observation in cancer etiology is that
the rate of malignancies in any mammalian population
increases exponentially as a function of age, suggesting a
mechanistic link between the cellular processes governing
longevity and carcinogenesis [33,34]. This observation is
even more stark when only considering human somatic
solid cancers [35]. When the data for human solid tumors
are presented as a function of increasing age, an intriguing
phenomenon is observed: a clear inflection point that
occurs at just after 50 years of age [36,37] (shown by a
circle in Figure 2A). This inflection point is preceded
by an initially gradual slope (referred to as the early or
E-slope) but is followed by a very steep curve (referred
Figure 2 Cancer incidence rises with age. (A) The incidence of
solid tumor cancers derived from somatic cells increases exponentially
with age. The circle marks the inflection point at the transition between
the early (E) slope and steep (S) slope. (B) The effect of sirtuin gene
expression on lifespan. This is a graphical summary of data obtained
from increased or decreased sirtuin expression in C. elegans.
Overexpression of sirtuin genes results in increased lifespan (curve C),
whereas underexpression of these genes shortened lifespan (curve B).
The time of the inflection point (circle) is shifted, but the general shape
of the survival curve remains unchanged.
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human cancer incidence after age 50 (Figure 2A).
These results strongly suggest that some change in, or
dysregulation of, critical biological processes and/or cellular
reparative pathways occurs at this inflection point, putting
us at an increased risk for somatic tumors [34]. However,
while it is tempting to suggest this is due to loss of a
specific protein family, that seems unlikely. It is more
reasonable to assume that the inflection point is due to a
large host of proteins and signaling pathways that main-
tain a cell's homeostatic poise. As such, our laboratory, as
well as many others, is interested in the changes that
occur in the cell at this critical inflection point that marks
the transition to the tumor-permissive phenotype.
This unique and potentially informative inflection
point that is observed in human somatic solid tumors
is also observed in almost all species, including mice
[38,39]. Analysis of this longevity data in multiple species,
C. elegans being a common example, shows an initial long,
flat slope, followed by an inflection point, and finally asteep curve [40-42], similar to the curve observed in
humans. While these results clearly suggest that both
aging and somatic human tumors share similar curves,
the more interesting question is whether there is a correla-
tive and/or mechanistic relationship between these two
curves that involves, at least in some part, the biology of
sirtuin proteins.
In this regard, several research groups, most notably
the Guarente laboratory, suggest that the time to the
inflection point of the longevity curve is directed, at
least in some part, by the sirtuin protein family. This
suggestion is based on the observation that overexpression
of the sirtuin proteins in C. elegans increased overall life-
span, while in contrast, deletion of these genes resulted in
the opposite effect [40-42]. Perhaps the most interesting
aspect of these seminal studies is that loss of and/or
enforced expression of the C. elegans sirtuins altered the
length of the early slope while the slope of the curve after
the inflection point remained unchanged (Figure 2B). This
result suggests two obvious possibilities: (1) the inflection
point is, to some degree, directed by sirtuin activity or
(2) there may be a threshold of cellular repair directed
by sirtuins, and at some point, cellular damage exceeds
repair, potentially playing a role in the appearance of
the inflection point. However, it is safe to assume that
there are likely many more plausible explanations as
well as other proteins that direct this cellular process.
Caloric restriction, mitochondrial energy metabolism,
aging, and human carcinogenesis
It is a well-established observation that animals on a CR
diet exhibit significant health-related effects, including
an increase in overall lifespan, which is, of course, also
dependent upon other nuanced factors [14,43,44]. However,
if one carefully analyzes these results, the closer a diet is to
the maximum CR level (i.e., 70% of ad libitum), the greater
the increase in murine longevity (Figure 3A) [45]. In
addition, it also appears to some significant extent that the
increase in lifespan is due to increasing the length of time
to reach the inflection point (Figure 3A) and not the other
portions of the longevity curve [45]. Furthermore, it is well
established that murine models genetically designed to
induce specific types of tumors also exhibit a decrease
in spontaneous disease when placed on a CR diet [46],
as shown by an example of a murine model of mutant
Kras-driven carcinogenesis (Figure 3B). Similarly, a de-
crease in spontaneous pancreas tumors was also observed
in a rat model for pancreas malignancies [47]. While there
are no rigorous data in humans that definitively link
either an increase in lifespan or decreased incidence of
malignancies to CR, there are multiple reports of soft
data to suggest this [33,34].
It is also well established that there is a strong relation-
ship between aging and mitochondrial function [48-51],
Figure 3 Effects of caloric restriction on murine survival and
carcinogenesis. (A) Overall survival or longevity in mice on a standard
ad libitum diet or CR diets consisting of 85, 50, or 40 kcal/week. The
black circles highlight the inflection points of the survival curves on the
ad libitum and 40 kcal/week diets. (B) The incidence of pancreatic
cancers in an LSL-KrasG12D genetic knock-in mouse model on either an
ad libitum diet or a CR diet. Results are presented as %survival or %tumor
free, respectively, as a function of mouse age.
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results in cellular damage that may include that due to
reactive oxygen species (ROS), mtDNA damage, etc. as
well as a decrease in lifespan. In this regard, three of the
seven mammalian sirtuins are found in the mitochondria,
including SIRT3 and SIRT4 [52]. These results suggest
that the mitochondrial sirtuins (or at least SIRT3 and
SIRT4) may respond to changes in cellular and nutrient
stress by modification of downstream target proteins
[27-31]. While this has not been clearly shown for SIRT4,
it has been shown that SIRT3 activity is activated by CR
and fasting [29-31].
If sirtuins, including the mitochondrial sirtuins, sense
nutrient status (i.e., fasting), it seems reasonable to
propose that one function of these proteins is to match
energy production to cellular need as well as energy con-
sumption. In addition, it would also suggest that the
regulation of the mitochondrial acetylome would play arole, at least in part, in matching cellular energy need to
availability [17,53]. Reversible acetylation of lysine is a
post-translational modification that neutralizes the
positive charge of this amino acid, potentially altering
the 3-dimensional structure of a protein as well as its
enzymatic function [54,55]. Thus, it has been proposed
that at least one function of the sirtuin gene family is
the regulation and maintenance of the metabolome via
the deacetylation of specific downstream target proteins
that direct the specific pathways in the mitochondria
that direct energy productions [15,56].
These results imply that sirtuins in general, and
mitochondrial sirtuins specifically, are nutrient status
sensing proteins that transmit a signal to downstream
target genes, as well as critical mitochondrial processes,
via protein deacetylation. We would propose that the
mitochondrial sirtuins respond to what has often been de-
scribed in most physiology courses as the fed versus the
fasting organismal/cellular state [57]. In our adaptation of
this model, it is proposed that in a fed state, the cells sense
that energy packets (i.e., food) are readily abundant and as
such, cellular processes are activated. This favors a pro-
metabolism, pro-aging, and pro-carcinogenic phenotype.
The activation of these processes, potentially induced by
insulin secretion from the pancreas, would inactivate
sirtuins, resulting in a general cellular state of increased
protein acetylation (Figure 4). In addition, insulin would
also activate a series of kinases that would activate pro-
metabolism, and it is suggested that these pathways would
result over time in aging and a carcinogenesis-permissive
phenotype. Finally, a pro-metabolism status may drive
aging at the organismal levels while different degrees of
aging may occur at the cellular and/or tissue/organ level,
and it is this combination of forces that results in the
more complex signs and symptoms of increasing age on a
species.
In contrast, when an organism is a fasting state, which
was likely quite often for evolutionarily primitive man, it
seems reasonable to propose that a metabolic state
would be established that maximizes the efficiency of en-
ergy generation as well as energy use. In this environment,
is seems reasonable to propose that the activity of the
mitochondrial sirtuins, as well as perhaps the entire sirtuin
family, would be activated, resulting in a generalized
deacetylated status (Figure 4). This would result in a
cellular phenotype that would be energy conserving, anti-
metabolism, anti-aging, as well as anti-carcinogenic.
However, this is presented as a very simplistic model
that may apply mostly to SIRT3 and the mitochondrial,
and it is clear that changes in both acetylation and
phosphorylation are much more complex as well as the
interplay between this PTM on specific proteins. Finally,
does this provide some insight as to why sirtuins might be
fidelity or TS proteins? In this regard, it could be proposed
Figure 4 Schema outlining the opposing effects of the kinome and the acetylome on metabolism in response to energy availability.
Fed conditions favor oxidative damage due to the induction of pro-metabolism pathways that are induced by insulin and other cytokines that
signal a high-energy availability status that would inactivate sirtuins. A fasting state is proposed to activate sirtuins and should induce cellular
pathways that conserve or increase cellular efficiency, resulting in energy conservation and preservation of cellular integrity.
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more efficient is the induction of pathways that might also
result in a cellular and/or organellar reparative phenotype.
Mitochondrial SIRT3 acts as a tumor suppressor
Lysine acetylation appears to be not only important but
also perhaps the primary post-translational modification
used to adapt cells to periods of fasting and to direct the
activity of specific mitochondrial proteins [58-60]. In this
regard, several proteomic surveys have identified a dis-
proportionately high number of acetylated proteins in
the mitochondria, which contain reversible acetyl-lysines
associated with energy homeostasis [23,61]. SIRT3 is the
primary mitochondrial deacetylase, and genetic knockout
of Sirt3 alters a significant number of mitochondrial
protein acetylation sites [62], including proteins involved in
the generation of ATP [26]. Therefore, it seems reasonable
to propose that lysine acetylation of mitochondrial proteins
may serve to both maintain and regulate overall mitochon-
drial metabolism and function. Therefore, we believe that
it is logical to hypothesize that SIRT3 acts as a metabolic
sensing protein to direct the regulation of mitochondrial
energy metabolism and ATP synthesis, the detoxification of
mitochondrial ROS, and other biological processes essential
for proper mitochondrial function. In addition, as discussed
above (Figure 4), it is likely that SIRT3 senses decreased
nutrient availability and responds by increasing the effi-
ciency of mitochondrial pathways that generate ATP,
shifting energy away from glycolysis and towards oxidative
phosphorylation.
It is a well-established observation that there is a link
between dysregulation of mitochondrial function in cancer
cells, which exhibit a significant increase in glycolysis, and
aberrant cellular metabolism. This link is commonly re-
ferred to as the “Warburg Effect” [26,63]. This has also
been observed to be a function of age, suggesting apotential mechanistic link between the cellular pro-
cesses governing mitochondrial function, longevity, and
the development of cancers [34]. Finally, tumor cells
also appear to have increased ROS levels that may be
due to aberrant metabolism, either through increased
production or decreased enzymatic detoxification, either of
which may result in oxidative stress and persistent oxidative
cell damage, adversely affecting genome stability. Increased
ROS levels are considered an early event in carcinogenesis
and, under specific cellular conditions, can further affect
cell dedifferentiation, tumor initiation, and progression.
These results provide strong evidence to support the
hypothesis that mitochondrial dysregulation plays a sig-
nificant role in the multi-hit process of cell transformation
and ultimately carcinogenesis. Based on these results, it
has been proposed that mitochondrial proteins, such as
SIRT3 and SIRT4, may function as critical regulators at
the crossroads between metabolism, aging, and aging-
related human illnesses such as cancer [64]. Finally, the
logical extension of this idea is that the loss of SIRT3
activity, by one of several potential mechanisms, would
create a cellular environment permissive for age-related
cancers [29].
Therefore, mice lacking the mitochondrial Sirt3 gene
were established to determine whether SIRT3 is a TS
protein, in which case, cells or mice lacking Sirt3 would
likely display a tumor-permissive phenotype. In this regard,
our laboratory has shown that mice lacking Sirt3 do not
exhibit an obvious or early in vivo phenotype or other
physiological abnormalities; however, the livers of these
mice exhibit a significant increase in acetylated mitochon-
drial proteins, as compared to the wild-type mice [62].
Moreover, when these mice or primary tissue cultures
derived from them were treated with various stress fac-
tors, such as oxidative stressors, chemical-hormonal, or
ionizing radiation, they displayed physiological phenotypes
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trophy [28,65], carcinogenesis [29,66,67], fatty liver
[27,68], radiation-induced liver damage [31], and age-
related hearing loss [32,64]. Interestingly, a common
observation in each of these studies showed loss of
Sirt3-induced higher steady-state levels of ROS as well
as oxidative stress.
While fidelity proteins, whether in the nucleus,
cytoplasm, or the mitochondria, appear to have multiple
downstream targets, it seems reasonable to suggest that
the observed increase in ROS levels in cells deficient
in SIRT3 may contribute to the development of age-
associated pathologies. Thus, loss of Sirt3 may induce
aberrant mitochondrial metabolism, and when the cells
are exposed to additional endogenous and exogenous
insults that also result in stress, there may be resultant
intracellular redox imbalance that may have deleterious
biological effects.
Therefore, there are two questions that must be ad-
dressed: (1) how does SIRT3 regulate mitochondrial
metabolic homeostasis? (2) What are the downstream
targets involved in this regulatory process?
Recent studies have demonstrated that Sirt3 regulates
the tricarboxylic acid cycle by deacetylating isocitrate
dehydrogenase [32], glutamate dehydrogenase (GDH)
[69], and acetyl-CoA synthetase [61,70]. SIRT3 also reg-
ulates the fatty acid cycle by deacetylating long-chain
acyl-coenzyme A dehydrogenase and 3-hydroxy-3-
methylglutaryl coenzyme A synthase 2 [26,60,70]. Our
group and others have observed that subunits of the
electron transport chain (complexes I–III and ATP syn-
thase) are also the substrates of SIRT3 [71,72]. In addition,
SIRT3 deacetylates manganese superoxide dismutase
(MnSOD), altering its activity of superoxide removal [31].
Combined, these results strongly suggest that SIRT3 is the
primary mitochondrial deacetylase serving to direct
mitochondrial energy production as well as to limit the
accumulation of mitochondrial ROS.
In vivo loss of Sirt3 in mice exhibit dysregulation of
mitochondrial functions including increased mitochon-
drial DNA damage in the liver, reduced ATP production,
an increase in mitochondrial ROS (including superoxide),
as well as increased ER/PR positive breast malignancies
[29]. Similarly, when Sirt3 knockout mouse embryonic
fibroblasts (MEFs) were challenged with various stress
factors, these cells had loss of contact inhibition and
were subsequently immortalized/transformed by infection
with a single oncogene, suggesting that SIRT3 may
function as a TS [29,31].
Interestingly, there is a significant decrease in SIRT3
levels in human tumors compared to normal tissue con-
trols. While these results appear to suggest that SIRT3 is
a genomically expressed, mitochondrially localized TS,
the mechanism through which SIRT3 protects againsttumorigenesis is unclear. As discussed, many substrates
of SIRT3 are tightly linked with energy homeostasis and
ROS production. Therefore, it has been suggested that
increased mitochondrial oxidative stress contributes to
human carcinogenesis. Our data support this hypothesis,
as murine breast tissue lacking Sirt3 exhibited an increase
in steady-state ROS. Similarly, human breast tissue
samples also displayed increased mitochondrial superoxide
levels coinciding with decreased Sirt3 expression. Sirt3−/−
mouse hepatocytes [28,29] and cardiomyoctes [28,65] also
presented with significantly higher basal superoxide levels,
which were observed to further increase when exposed to
different types of exogenous cellular stress.
In recent years, three seminal papers have been pub-
lished that demonstrated that deacetylation of MnSOD by
SIRT3 directs its enzymatic activity [30,31,73]. Further-
more, in several tissue culture experiments, co-infection
of lenti-MnSOD not only decreased mitochondrial super-
oxide levels but also prevented immortalization of Sirt3−/−
MEFs by a single oncogene [31]. These experiments were
confirmed using a MnSOD construct in which lysine 122
was mutated to arginine (MnSOD122K-R), resulting in
a constitutively active, dominant positive protein [31].
Co-infection of lenti-MnSOD122K-R also prevented
immortalization of Sirt3−/− MEFs by a single oncogene.
In contrast, co-infection with dominant negative mutant
MnSOD gene (lenti-MnSOD122K-Q) mimicking a consti-
tutively acetylated lysine failed to prevent immortalization
by infection with a single oncogene [31]. Finally, it has also
been shown that infection with the lenti-MnSOD122K-R
gene prevented tissue culture transformation with ex-
ogenous agents, including ionizing radiation and stress-
induced increases in cellular ROS [31]. These experiments
strongly suggest that aberrant mitochondrial superoxide
metabolism plays a significant role in the tumor-
permissive phenotype (Figure 5) observed in cells lacking
Sirt3.
Many studies also suggest that changes in the steady
state level of ROS may play a critical role in how the
mitochondria communicate with other parts of the cell
and further lead to changes in gene expression, cell prolif-
eration, and apoptosis [29,74-78]. In support of this hy-
pothesis, Venkataraman et al. showed that overexpression
of MnSOD in PC-3 cells resulted in a delay of the G1-S
phase transition. This delay was mediated in part by
modulation of the redox status of the cell through the
increased levels of H2O2 [79]. In addition, Karawajew
et al. demonstrated that mitochondrial ROS serve as
second messengers by guiding p53 translocation to the
mitochondria, leading to the activation of apoptosis and
p53 target gene expression [75]. They also showed that
treatment of cells with oligomycin, an inhibitor of ATP
synthase, prevents stress-induced mitochondrial accumu-
lation of p53 and abrogates p53-dependent apoptosis by
Figure 5 Schema outlining the multiple mechanisms by which SIRT3 blocks ROS production, thereby preventing carcinogenesis. Loss of
SIRT3 results in mitochondrial dysregulation as well as increased ROS, due in part to increased mitochondrial protein acetylation, including
that in MnSOD, and decreased MnSOD detoxification activity as well as other downstream target proteins deacetylated by SIRT3. The increase
in ROS is thought to be an early event in the in vivo carcinogenesis observed in mice lacking Sirt3.
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strongly support the hypothesis that the alteration of
mitochondrial ROS production, via changes in MnSOD
enzymatic activity (Figure 5) or mitochondrial metabolic
homeostasis, represents a potential mechanism for inter-
compartmental cellular communication and may play a
role in SIRT3 deficiency-induced aging-related cancers.
Finally, several studies also indicate that the acetylation
statuses of SIRT3 substrates like acetyl-CoA synthetase,
GDH, long-chain acyl-CoA dehydrogenase (LCAD),
succinate dehydrogenase, and mitochondrial ribosome
subunit MRPL10 are frequently altered in human cancers.
Interestingly, SIRT3 has also been shown to have pro-
apoptotic or anti-apoptotic effects on different cell types,
and at least one mechanism involves deacetylating Ku70,
preventing the release of BAX into mitochondria [80].
Although the detailed mechanism of the connection be-
tween these mitochondrial protein acetylation and car-
cinogenesis events is still unclear, these results provide
evidence that the mitochondrial acetylome may play
an important role in the cellular damage and tumor-
permissive phenotype (Figure 5).SIRT4 functions as tumor suppressor by directing
glutamine metabolism
Recent evidence suggests that SIRT4 may also have a
role in cell metabolism and carcinogenesis. Like SIRT3,
SIRT4 regulates metabolic function through variety of
mechanisms. While SIRT3 directs post-translational
modifications via protein deacetylation, SIRT4 affects
its targets largely through NAD-dependent ADP-
ribosylation (Figure 6) [20]. SIRT4 is expressed in severalcell types including liver, kidney, testis, striated muscle,
and vascular smooth muscle as well as the insulin-
producing β cells in the islets of Langerhans [81].
SIRT4 is activated in response to genotoxic stress and is
required for the block in glutamate metabolism allowing
for a proper DNA damage response [82]. While SIRT4
exhibits no deacetylase activity on histones or serum
albumin [81], recent findings suggest SIRT4 deacetylates
malonyl CoA decarboxylase (MCD) under low nutrient
conditions. MCD produces acetyl CoA from malonyl
CoA, the latter providing a carbon skeleton for lipogenesis
under nutrient-rich conditions [83]. When deacetylated by
SIRT4, MCD functions less efficiently, and animals lacking
SIRT4 present with increased MCD activity, dysregulated
lipid metabolism, and protection against diet-induced
obesity (Figure 6). Therefore, SIRT4 opposes fatty acid
oxidation, promoting lipid anabolism by regulating MCD
function/malonyl CoA levels [83]. Similarly, in both
myocytes and hepatocytes, loss of SIRT4 increased fatty
acid oxidation gene expression and cell respiration [84].
In pancreas β cell mitochrondria, SIRT4 serves to ADP-
ribosylate GDH, a mitochondrial enzyme that converts
glutamate to α-ketoglutarate, the activity of which is also
modulated by ADP-ribosylation [85]. GDH promotes
glutamine/glutamate metabolism, facilitating ATP pro-
duction and insulin secretion. Once ADP-ribosylated,
the enzymatic function of GDH is repressed, leading to
\reduced ATP synthesis and less effective insulin secretion
in response to exogenous amino acids [86,87].
Clinically, SIRT4 mRNA expression is reduced in several
malignancies, including breast, colon, bladder, gastric,
ovarian, and thyroid cancers, though SIRT4 loss was par-
ticularly pronounced in lung cancer patients (Figure 6).
Figure 6 Schema outlining the proposed pathway by which SIRT4 regulates proliferation. It is proposed that under nutrient rich conditions
mTORC1 inhibits CREB2, decreasing the expression of SIRT4. When SIRT4 activity is decreased, which is observed in the Sirt4 knockout mice, and what
might be expected with increasing age, the glutamate/αketoglutarate and TCA cycles are dysregulated. As such, it is suggested that this plays a role,
at least in some part, in the tumor-permissive phenotype in mice lacking Sirt4.
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present with a variety of solid tumors, though most fre-
quently lung tumors [86,88]. In addition, loss of SIRT4
corresponds with increased aggressiveness in women with
breast cancer. Furthermore, overexpression of SIRT4
opposes cell proliferation, transformation, and tumor
progression as shown in an in vivo murine model [89].
Similarly, loss of SIRT4 accelerates Myc-induced B cell
lymphomagenesis in mice lacking Sirt4, and SIRT4
overexpression sensitizes cells to apoptosis induced by
glycolysis inhibitors [88].
Combined, these observations strongly suggest that
SIRT4 has tumor-suppressive effects and that its down-
regulation may serve to facilitate the progression of
several human cancers. Loss of SIRT4 appears to be a
result of mammalian target of rapamycin complex 1
(mTORC1), a complex consisting of mTOR, Raptor,
and mLST8 that is dysregulated in human cancers and
activated under nutrient-rich conditions [90]. mTORC1
leads to proteasome-mediated destabilization of cAMP-
responsive element binding 2 (CREB2), a key transcrip-
tional regulator of SIRT4. By destabilizing CREB2,
mTORC1 reduces SIRT4 expression, thereby increasing
GDH activity and glutamine/glutamate metabolism [89].Conclusions
The results discussed above suggest that loss of a single
mitochondrial protein leads to the aberrant regulation
of the mitochondrial acetylome signaling network that
responds to metabolic demands and deacetylates down-
stream target proteins, resulting in a phenotype permis-
sive for human illnesses associated with aging. In this
regard, it is proposed that SIRT3 and SIRT4 respond to
changes in cellular nutrient status to alter the enzymatic
activity of specific downstream targets to maintain en-
ergy production that matches energy availability and
ATP consumption. As such, it is proposed that loss of
function or genetic deletion of these mitochondrial
genes results in a mismatch of mitochondrial energy me-
tabolism, culminating in a cell phenotype permissive for
transformation and tumorigenesis. As such, we believe
that the Sirt3 and Sirt4 knockout mice represent a new
paradigm that mechanistically links mitochondrial me-
tabolism, the acetylome post-translational signaling net-
work, and age-related disease including carcinogenesis.
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